About this trial
Point-of-care ultrasound (POCUS) is the use of ultrasound by the bedside provider in real time to answer a specific question and guide medical management. POCUS can be used to diagnose the severity of neonatal respiratory distress syndrome (RDS) through a lung ultrasound score. Lung ultrasound scores have also been shown to predict if an infant is treated with an initial dose of surfactant. Therefore, using lung ultrasound scores to guide surfactant therapy for RDS will likely lead to earlier surfactant therapy and may improve short-term respiratory outcomes. This study will test this theory by comparing lung ultrasound score-guided surfactant therapy for premature infants with RDS with our current surfactant administration guidelines.
Eligibility criteria
Qualifiers
The infant's parent/legal guardian can understand and willingly sign a written informed consent document for this study
Birth gestational age between 27w0d-36w6d
Diagnosis of respiratory failure secondary to RDS requiring respiratory support with non-invasive positive pressure ventilation
Disqualifiers
Unable to obtain lung ultrasound between 1-2 hours of life
Infants already intubated or received surfactant before the point of care lung ultrasound
Infants born with congenital cardiac disease, congenital lung disease, or congenital facial/airway malformations
Infants born with chromosomal abnormalities
Trial design
Treatments tested in this trial
- Echography-guided Surfactant THERapy (ESTHER)